Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early diagnosis cuts Singapore TB (tuberculosis) rates:

This article was originally published in Clinica

Executive Summary

The key component of Singapore's successful TB elimination programme is early diagnosis, the results of which continue to be seen after 10 years of declining incidence. According to Singapore's health ministry, the number of cases and new incidence has declined steadily over the past decade. Between 1997 and 2006, the number of cases dropped form 1,712 to 1,256, and the rate per 100,000 of population in 2006 was 34.8, down from 54.9 in 1997 and 37 in 2005. The Singapore Tuberculosis Elimination programme (STEP) was set up in 1997 - this and concerted efforts by the medical community are said to be primarily responsible for the decline of the air-borne disease.

You may also be interested in...

RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.



FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts